Abstract:Abstract Therapy resistance is responsible for 90% of cancer-related deaths. We identified a novel mechanism of therapy resistance in which cancer cells enter an endocycling cell state, undergoing repeated S and G phases without dividing. As a result, resistant endocycling cells are 40 times larger than mitotic cancer cell controls. Interestingly, we observed that these non-proliferative endocycling cells can eventually give rise to proliferative progeny weeks after chemotherapy is removed, modeling cancer recurrence. We hypothesize that this endocycling cancer cell state is a critical driver of therapy resistance and cancer lethality. We evaluated oxidative stress in endocycling cells that survived the days and weeks following chemotherapy treatment using DCF-DA staining. We found increased levels of reactive oxygen species (ROS) in endocycling prostate cancer cells compared to untreated mitotic cells when normalized to cell size. Given that mitochondria are major producers and regulators of ROS, we hypothesize that cells surviving in this resistant state alter mitochondrial structure and function in response to increased oxidative stress. We performed immunofluorescence and confocal microscopy on mitochondria in untreated cells and cells following chemotherapy treatment to observe their morphology. Surviving endocycling cells had increased mitochondrial fragmentation when compared to the untreated group, a result that was further supported by reduced expression of phospho-DRP1 Ser637 via western blot. To assess changes in glucose metabolism, we then utilized isotope tracing-based metabolomics with [U-13C]glucose on untreated and surviving endocycling cells following chemotherapy. Endocycling cells had decreased labeling of 13C in TCA cycle metabolites, suggesting a decrease in mitochondrial function when compared to untreated cells. Ongoing work involves further studying metabolic reprogramming as cells enter this resistant state with parallel labeling experiments using [1,2-13C]glucose and [U-13C]glutamine to perform mathematical modeling-based 13C-metabolic flux analysis. In addition, we engineered a cell line to track mitochondria in real-time to quantify mitochondrial dynamics underlying the morphology observed in untreated and surviving cells. Our goal is to characterize how this therapy-resistant cell state alters its mitochondrial structure and function to survive therapeutic stress. Identifying vulnerabilities of this phenotype will enable new approaches for eliminating drug resistance in cancer. Citation Format: Melvin Li, Sarah R. Amend, Kenneth J. Pienta. Therapy-resistant endocycling cancer cells alter mitochondrial structure and metabolism to survive therapeutic stress [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6612.

Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance

Modulation of Mitochondrial Metabolic Reprogramming and Oxidative Stress to Overcome Chemoresistance in Cancer

Mitochondrial signaling pathways and their role in cancer drug resistance

Research Progress on Mitochondria Regulating Tumor Immunity.

Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells

Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management

Targeting Mitochondrial Biogenesis to Overcome Drug Resistance to MAPK Inhibitors

Mitochondria Targeting as an Effective Strategy for Cancer Therapy

Genetic mutations affecting mitochondrial function in cancer drug resistance

Mitochondrial regulation in the tumor microenvironment: targeting mitochondria for immunotherapy

Abstract A52: Overcoming Mitochondrial Oxidative Phosphorylation-Mediated Resistance to Targeted Therapies in Melanoma

Resistance Of Cancers To Immunologic Cytotoxicity And Adoptive Immunotherapy Via X-Linked Inhibitor Of Apoptosis Protein Expression And Coexisting Defects In Mitochondrial Death Signaling

Mitochondrial Immune Regulation and Anti-Tumor Immunotherapy Strategies Targeting Mitochondria

Altered cancer metabolism in mechanisms of immunotherapy resistance

Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance

Manipulating mitochondrial electron flow enhances tumor immunogenicity

Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype

Abstract 6612: Therapy-resistant endocycling cancer cells alter mitochondrial structure and metabolism to survive therapeutic stress

Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition

Targeting Mitochondrial Oxidative Phosphorylation in Glioblastoma Therapy

Mitochondrial Metabolism in Melanoma